Brean Capital analyst Difei Yang was out pounding the table on Zogenix, Inc. (NASDAQ:ZGNX) Wednesday, reiterating a Buy rating and price target of $2.
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced that it is implementing …
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has …
Biopharmaceutical company Zogenix (NASDAQ: ZGNX) announced on Tuesday that it will be selling its painkiller drug, Zohydro, to Pernix Therapeutics Holdings Inc (NASDAQ: PTX) …
In a research report issued on March 11, Brean Capital analyst Difei Yang reiterated a Buy rating on Zogenix, Inc. (NASDAQ:ZGNX) with a price …
Brean Capital’s healthcare analyst Difei Yang weighed in this morning with a few insights on Zogenix (NASDAQ:ZGNX), after the healthcare research firm Symphony Health Solutions …
In a research report released Monday, Brean Capital analyst Difei Yang maintained a Buy rating on Zogenix (NASDAQ:ZGNX) with a $2.50 price target, …
Before the market opened Tuesday, Brean Capital analyst Difei Yang maintained a Buy rating on Zogenix (NASDAQ:ZGNX) with a price target of $2.50, …
In a research report issued Tuesday, Oppenheimer analyst Akiva Felt maintained an Outperform rating on Zogenix (NASDAQ:ZGNX) with a price target of $2.50, …
In a research note published today, Oppenheimer analyst Akiva Felt maintained an Outperform rating on Zogenix (NASDAQ:ZGNX) with a $2.50 price target, as the …
